GeneDx Holdings Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for GeneDx Holdings Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
02/19/2025 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $70 → $80 | Maintains | Neutral | Get Alert |
01/07/2025 | Buy Now | — | TD Cowen | Dan Brennan71% | $75 → $118 | Maintains | Buy | Get Alert |
10/30/2024 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $54 → $70 | Maintains | Neutral | Get Alert |
10/30/2024 | Buy Now | — | Wells Fargo | Brandon Couillard70% | $34 → $75 | Maintains | Equal-Weight | Get Alert |
10/30/2024 | Buy Now | — | Craig-Hallum | Bill Bonello70% | $70 → $95 | Maintains | Buy | Get Alert |
10/24/2024 | Buy Now | — | Craig-Hallum | Bill Bonello70% | $46 → $70 | Maintains | Buy | Get Alert |
10/16/2024 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $32 → $54 | Maintains | Neutral | Get Alert |
08/27/2024 | Buy Now | — | Wells Fargo | Brandon Couillard70% | → $34 | Initiates | → Equal-Weight | Get Alert |
07/31/2024 | Buy Now | — | TD Cowen | Dan Brennan71% | $46 → $50 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | — | BTIG | Mark Massaro71% | $35 → $45 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | — | Craig-Hallum | Bill Bonello70% | $43 → $46 | Maintains | Buy | Get Alert |
07/31/2024 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $28 → $32 | Maintains | Neutral | Get Alert |
07/17/2024 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $12.5 → $28 | Maintains | Neutral | Get Alert |
07/10/2024 | Buy Now | — | Craig-Hallum | Bill Bonello70% | → $43 | Initiates | → Buy | Get Alert |
06/26/2024 | Buy Now | — | BTIG | Mark Massaro71% | $19 → $35 | Maintains | Buy | Get Alert |
04/30/2024 | Buy Now | — | TD Cowen | Dan Brennan71% | $14 → $24 | Maintains | Buy | Get Alert |
04/30/2024 | Buy Now | — | BTIG | Mark Massaro71% | $15 → $19 | Maintains | Buy | Get Alert |
04/22/2024 | Buy Now | — | BTIG | Mark Massaro71% | $11 → $15 | Maintains | Buy | Get Alert |
04/15/2024 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $6 → $11 | Maintains | Neutral | Get Alert |
11/01/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $7 → $6 | Maintains | Neutral | Get Alert |
08/09/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $8 → $7 | Maintains | Neutral | Get Alert |
07/24/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $9 → $8 | Maintains | Neutral | Get Alert |
07/21/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $9 → $8 | Maintains | Neutral | Get Alert |
05/15/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes26% | $33 → $9 | Maintains | Neutral | Get Alert |
The latest price target for GeneDx Holdings (NASDAQ:WGS) was reported by Goldman Sachs on February 19, 2025. The analyst firm set a price target for $80.00 expecting WGS to fall to within 12 months (a possible -8.35% downside). 19 analyst firms have reported ratings in the last year.
The latest analyst rating for GeneDx Holdings (NASDAQ:WGS) was provided by Goldman Sachs, and GeneDx Holdings maintained their neutral rating.
There is no last upgrade for GeneDx Holdings
There is no last downgrade for GeneDx Holdings.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Holdings was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.
While ratings are subjective and will change, the latest GeneDx Holdings (WGS) rating was a maintained with a price target of $70.00 to $80.00. The current price GeneDx Holdings (WGS) is trading at is $87.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.